Tirzepatide

Tirzepatide in South Africa: Price, Dosage & 2026 Guide

Product	Typical ZAR price/month
Mounjaro (branded)	R3,500–R6,500 (private pharmacy)
Zepbound (branded)	Not registered in SA [2]	Not legally available
HD Labs / Body Pharm tirzepatide	Compounded, unregistered [9]	R1,800–R3,200
HD Tirsema 44 (tirz + sema combo)	Compounded, unverified ratio [9][20]	R2,500–R3,800

Key Takeaways

• Tirzepatide works via dual GIP/GLP-1 receptor activation, producing stronger metabolic effects than single-receptor agonists
• Standard dosing starts at 2.5 mg weekly and escalates by 2.5 mg every four weeks to a maximum of 15 mg
• Absolute contraindications include medullary thyroid carcinoma history, MEN2 syndrome, and known hypersensitivity
• Branded Mounjaro costs R8,000–R12,000/month privately; compounded pens range R1,800–R3,500 per multi-dose pen
• Compounded tirzepatide carries regulatory and safety risks that branded Mounjaro does not

What Is Tirzepatide? The Dual-Receptor Mechanism Explained

Receptor pathway	Primary clinical effect
GLP-1 (glucagon-like peptide-1)	Slows gastric emptying, suppresses appetite, stimulates glucose-dependent insulin secretion
GIP (glucose-dependent insulinotropic polypeptide)	Amplifies insulin response after meals, may improve adipose-tissue insulin sensitivity and lipid handling

Why dual agonism outperforms GLP-1 alone

GLP-1 activation alone (as with semaglutide) reduces appetite and slows digestion. Adding GIP agonism enhances the metabolic response in fat tissue and amplifies insulin secretion at the pancreas. GIP signalling improves how the body handles glucose and stored fat; GLP-1 signalling delays stomach emptying and acts on brain satiety centres.

In SURMOUNT-1, adults with obesity but without diabetes lost a mean of 20.9% of body weight on 15 mg weekly tirzepatide over 72 weeks, versus 3.1% on placebo [17]. SURMOUNT-3 reported a total mean loss of roughly 25% when tirzepatide followed a 12-week intensive lifestyle programme [19].

What that means in practice

Tirzepatide reduces hunger and food intake through the combined action of both receptor pathways. SURMOUNT-4 showed the effect is treatment-dependent: participants who stopped tirzepatide after a 36-week lead-in regained 14% of body weight, while those who continued lost a further 5.5% [20]. Weight loss tracks active drug exposure, not behaviour change alone.

The locally available compounded options, such as the HD Labs Tirzepatide 30 and the higher-dose Body Pharm Tirzepatide 60 Pen, claim to deliver the same molecule. Potency and dose accuracy are not independently verified [4][13].

Tirzepatide Dosage Schedule: Starting Dose to Maximum

Tirzepatide is administered as a once-weekly subcutaneous injection into the abdomen, thigh, or upper arm. The standard schedule starts at 2.5 mg and increases by 2.5 mg every four weeks to a maximum of 15 mg [4]. The 2.5 mg starting dose is a tolerance dose, not a therapeutic one — it allows the body to adapt to GI side effects before therapeutic doses begin. Therapeutic effect begins at 5 mg and scales with each step.

The standard FDA-approved titration ladder

Week	Weekly dose	Purpose
1–4	2.5 mg	Initiation; GI tolerance
5–8	5 mg	First therapeutic dose
9–12	7.5 mg	Optional intermediate step
13–16	10 mg	Common maintenance dose
17–20	12.5 mg	Optional intermediate step
21+	15 mg	Maximum dose

Increases happen every four weeks at minimum, and only if the prior dose is tolerated [4]. Many patients stabilise at 5 mg or 10 mg rather than pushing to 15 mg, particularly when nausea, constipation, or reflux flare.

Why slow titration matters

GI side effects (nausea, vomiting, diarrhoea, constipation) are dose-dependent and most intense in the first 1–2 weeks after each step-up. The gut receptors are being activated at higher concentrations. The four-week interval lets receptors adapt and gastric emptying recalibrate, reducing nausea and vomiting severity. Jumping straight to 10 or 15 mg from a low dose materially increases the risk of severe nausea and dehydration. In SURMOUNT-1, the discontinuation rate due to adverse events tracked with dose [20].

Calculating doses from compounded multi-dose pens

Branded Mounjaro KwikPens deliver a single fixed dose per pen. Local compounded products are different: they are multi-dose devices where you draw or dial a fraction of the total. The HD Labs Tirzepatide 30 is marketed as 30 mg total per pen, which on a 5 mg/week schedule notionally yields six weekly doses, or twelve doses at 2.5 mg [1][2]. The Body Pharm Tirzepatide 60 Pen is advertised at 60 mg total, notionally covering 10–12 weeks of titration from 2.5 mg upward [1][2].

Tirzepatide Side Effects: Full Safety Profile for 2026

Tirzepatide carries a boxed warning for thyroid C-cell tumours, including medullary thyroid carcinoma, based on rodent carcinogenicity data, and is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) [18]. This warning applies to every tirzepatide product, branded or compounded, because the active molecule is identical.

The boxed warning and absolute contraindications

Common and serious side effects at a glance

Category	Effects	Notes
Boxed warning	Thyroid C-cell tumours, medullary thyroid carcinoma	Contraindicated in MTC/MEN2 history [18]
Common GI (≥5%)	Nausea, vomiting, diarrhoea, constipation, abdominal pain, dyspepsia	Dose-dependent, worst in first 1–2 weeks after each step-up [21]
Serious	Acute pancreatitis, gallbladder disease (cholelithiasis, cholecystitis), acute kidney injury from dehydration	Stop and seek care for severe abdominal pain radiating to the back [18]
Cardiovascular	Resting heart rate increase of ~2–4 bpm	Monitor in patients with arrhythmia history [18]
Metabolic	Hypoglycaemia, especially when combined with insulin or sulfonylureas	Dose reduction of co-therapy often required [18]
Other	Injection-site reactions, hypersensitivity, diabetic retinopathy complications in T2D, suicidal ideation (post-marketing signal under review)	[18]

When to stop and seek medical help

Stop tirzepatide and contact a doctor immediately if you experience any of the following:

• Severe, persistent abdominal pain, particularly radiating to the back (possible pancreatitis)
• A new neck lump, hoarseness, or trouble swallowing
• Right upper-quadrant pain, fever, or jaundice (possible gallbladder disease)
• Signs of severe dehydration from prolonged vomiting or diarrhoea, especially with reduced urine output
• Symptoms of severe hypoglycaemia: confusion, sweating, tremor, loss of consciousness
• Facial or throat swelling, rash, or breathing difficulty (hypersensitivity)

In SURMOUNT-1, discontinuation due to adverse events rose with dose, and the GI events that drove most stoppages clustered around titration steps [21]. Compounded multi-dose pens with unverified concentration add a further variable: if a draw delivers more than the intended milligrams, side-effect severity scales accordingly [1][20].

Tirzepatide Price in South Africa: 2026 ZAR Comparison

Compounded tirzepatide in South Africa ranges from roughly R1,800 to R3,500 per multi-dose pen in 2026, while branded Mounjaro, sold through private pharmacies on prescription, typically lands in the R8,000–R12,000 per month band at maintenance doses, with Zepbound not separately registered locally [1][3][4]. The table below was verified in February 2026 against the Beskinny storefront and published price references.

Product	Format	Total tirzepatide	Price (ZAR)	Approx. cost per mg	Local availability
Mounjaro (Eli Lilly, branded)	Single-use vial / KwikPen	Varies by strength (2.5–15 mg weekly)	~R8,000–R12,000/month (private script)	Not directly comparable
Zepbound (Eli Lilly, branded)	Multi-dose pen	Varies by strength	Import only; ~R18,000–R19,000/month equiv. at US list price	Not directly comparable
HD Labs Tirzepatide 30	Multi-dose vial	30 mg	R1,800	~R60/mg
HD Labs Tirzepatide 30 mg Pen	Multi-dose pen	30 mg	R2,100	~R70/mg
Body Pharm Tirzepatide 60 Pen	Multi-dose pen	60 mg	R3,500	~R58/mg

How to read these numbers

Per-mg cost is the cleanest like-for-like metric across compounded pens, but it does not equal cost per weekly dose. A standard titration starts at 2.5 mg/week and steps up to 5, 7.5, 10, 12.5, or 15 mg, so a single 60 mg pen could cover anywhere from four weeks (15 mg maintenance) to roughly 12 weeks (early titration) of injections.

Branded context

US list prices sit near US$1,023/month for Mounjaro and US$1,060/month for Zepbound (2024–2025 data, GoodRx and KFF) — roughly R18,000–R19,000/month at R18/US$ before insurance or rebates [10][11][12]. South African Mounjaro pricing through Aspen channels is materially lower than US list, but still 3–5× the cost of local compounded pens [1][3]. Prices change frequently; reconfirm at point of purchase.

Branded vs Compounded Tirzepatide: Key Differences

Dimension	Branded (Mounjaro/Zepbound)	Compounded peptide tirzepatide (SA)
Regulatory approval
Manufacturing	Eli Lilly GMP-certified facilities	Compounding pharmacies or peptide labs; no harmonised SA standard [3][10]
Purity & sterility	Batch-tested, published stability and impurity data per FDA/EMA filings [1]	Quality depends on supplier; no public certificates of analysis for HD Labs or Body Pharm products [5][6]
Dose precision	Pre-filled, fixed-dose pen (2.5/5/7.5/10/12.5/15 mg clicks) [1]	Multi-dose vials/pens; user measures volume by units on syringe or pen dial; concentration not always disclosed [5]
Price (SA, 2025–2026)	~R8,000–R12,000/month private script for Mounjaro; Zepbound ~R18,000–R19,000 equiv. at US list [10][11]	R1,800 (HD Labs Tirzepatide 30) to R3,500 (Body Pharm Tirzepatide 60 Pen) per pen [4]
Compounded on a named-patient basis under the Medicines Act and GPP rules; legally grey when mass-marketed online [9][10]
Clinical evidence	All SURMOUNT trials (SURMOUNT-1 through -4) used Eli Lilly's branded tirzepatide [17][18][19][20]	Zero RCT data; efficacy and safety inferred, not demonstrated

Why some patients still choose compounded

The trade-offs you accept

Available Tirzepatide Products at Beskinny: Dosages & Formats

Product	Format	Total tirzepatide	Marketed use case
HD Labs Tirzepatide 30	Multi-dose vial	30 mg	Initiation and early titration (2.5–5 mg weekly), ~6–10 weeks of supply [3]
HD Labs Tirzepatide 30 mg Pen	Pre-filled multi-dose pen	30 mg	Same total dose as the vial, delivered via metered pen for users who prefer not to draw with a syringe [3]
Body Pharm Tirzepatide 60 Pen	Pre-filled multi-dose pen	60 mg	Mid-to-late titration (7.5–15 mg weekly); roughly 4–8 weeks of supply depending on dose [10]
HD Tirsema 44 Pen	Pre-filled multi-dose pen	44 mg total peptide (tirzepatide + semaglutide combination; exact ratio not disclosed by the compounder)	Marketed as a dual-agonist option; ratio and pharmacokinetics are unverified [3][16]

Concentration in mg/mL and the exact number of metered clicks per pen are not consistently published by either compounder, so dose accuracy depends on the dispensing pharmacist's instructions [3][10]. I treat any printed "10-week schedule" on these pens as a marketing estimate, not a validated dose count.

Storage and injection basics

Store all four products in a fridge at 2–8°C and never freeze them. Eli Lilly's prescribing information for branded Mounjaro allows up to 21 days at room temperatures below 30°C once in use [7]. Compounded pens have no equivalent stability data, so I default to keeping them refrigerated except during the injection itself. Inject subcutaneously into the abdomen, thigh, or upper arm once weekly, rotating sites, and discard any pen showing cloudiness, particulates, or discolouration.

Browse the full tirzepatide range at Beskinny before deciding which strength matches your current titration step.

Who Should Not Use Tirzepatide: Contraindications

Tirzepatide is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN2), or a known hypersensitivity to tirzepatide or any excipient in the formulation [7]. These are absolute contraindications carried directly from Eli Lilly's prescribing information for Mounjaro and apply equally to compounded peptide versions sold locally, because the active molecule is the same [7].

The relative cautions are broader and require a prescriber's judgement rather than a self-assessment.

Category	Condition	Why it matters
Absolute	Personal/family history of MTC	Rodent studies showed dose-dependent thyroid C-cell tumours; human risk unquantified [7]
Absolute	MEN2 syndrome	Elevated baseline risk of medullary thyroid cancer [7]
Absolute	Hypersensitivity to tirzepatide	Risk of anaphylaxis and angioedema [7]
Caution	History of pancreatitis	Acute pancreatitis reported in SURMOUNT and SURPASS trials [13][14]
Caution	Severe gastroparesis or GI disease	Tirzepatide slows gastric emptying and can worsen symptoms [7]
Caution	Pregnancy or breastfeeding	No adequate human data; discontinue if pregnancy is planned [7]
Not indicated	Type 1 diabetes
Caution	Severe renal impairment	Dehydration from GI side effects can precipitate acute kidney injury [7]

Compounded tirzepatide from HD Labs or Body Pharm has no separate safety dataset, so the same exclusions apply. A South African doctor must screen for thyroid history, pancreatitis, and renal function before prescribing, and continue monitoring at each dose escalation. This is not a medication to source and self-administer based on a friend's experience.

Tirzepatide vs Other Weight Loss Options in South Africa

Option	Mechanism	Best evidence (weight loss)	SA status 2026
Tirzepatide (Mounjaro)	Dual GIP/GLP-1 agonist	−20.9% at 72 weeks, 15 mg (SURMOUNT-1) [18]
Semaglutide (Ozempic/Wegovy)	GLP-1 agonist	−9.6% HbA1c-matched weight loss vs tirzepatide's −13.1% (SURPASS-2, 40 weeks)	Ozempic registered for T2D; Wegovy not yet locally registered [3]
Retatrutide	Triple GIP/GLP-1/glucagon agonist	Up to −24.2% at 48 weeks (Phase 2)	Not approved anywhere; compounded peptide only
Oral weight-loss tablets	Various (appetite suppressants, lipase inhibitors)	Typically 3–8% over 12 months	Several registered, weaker evidence

Semaglutide: the closest registered alternative

In SURPASS-2, tirzepatide 15 mg weekly produced larger HbA1c and body-weight reductions than semaglutide 1 mg weekly over 40 weeks in adults with type 2 diabetes. For weight-loss-focused users in South Africa, Wegovy (semaglutide 2.4 mg) is not yet locally registered, so the practical choice is often between Mounjaro and compounded tirzepatide pens like the HD Labs Tirzepatide 30 or the higher-strength Body Pharm Tirzepatide 60 Pen [3].

Retatrutide: the next-generation contender

Frequently Asked Questions: Tirzepatide South Africa 2026

Is tirzepatide available in South Africa?

Do I need a prescription for tirzepatide in South Africa?

How long does it take for tirzepatide to work?

Appetite suppression typically begins within 1–2 weeks of the first 2.5 mg dose, with clinically meaningful weight loss emerging from week 12 onward as the dose escalates. In SURMOUNT-1 (Jastreboff et al., JAMA 2022), mean weight loss reached −15.0% to −20.9% by week 72 at maintenance doses of 5–15 mg weekly [21].

Can I use tirzepatide if I don't have diabetes?

What is the difference between tirzepatide and semaglutide?

Tirzepatide is a dual GIP/GLP-1 receptor agonist; semaglutide is a GLP-1 agonist only. In the head-to-head SURPASS-2 trial in type 2 diabetes, tirzepatide 15 mg produced larger HbA1c and weight reductions than semaglutide 1 mg over 40 weeks [1].

Is compounded tirzepatide safe?

Compounded tirzepatide carries higher uncertainty than branded Mounjaro. Potency, sterility, and beyond-use dating of products like the HD Labs Tirzepatide 30 or Body Pharm Tirzepatide 60 Pen are not independently verified, and the US FDA has moved to restrict compounded tirzepatide since the 2024 shortage resolution [6][8].

Next Steps: How to Source Tirzepatide Safely in South Africa